Reata Pharmaceuticals (RETA) is Initiated by Citigroup to Buy

Reata Pharmaceuticals (RETA) was Initiated by Citigroup to “Buy”. Citigroup advised their investors in a research report released on Jun 20, 2016.

Many Wall Street Analysts have commented on Reata Pharmaceuticals. Piper Jaffray Initiated Reata Pharmaceuticals on Jun 20, 2016 to “Overweight”, Price Target of the shares are set at $33.

Reata Pharmaceuticals

Leave a Reply

Reata Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Reata Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.